FDA Accepts Supplement for Repatha (Evolocumab) by Amgen
The FDA has accepted a supplemental application for Repatha (evolocumab) from Amgen.
Therapeutic Area
Therapeutic area intelligence for PCSK9 Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.